Pharmacokinetics of tirilazad and U-89678 in ischemic stroke patients receiving a loading regimen and maintenance regimen of 10 mg/kg/day of tirilazad

Journal of Clinical Pharmacology

Volumn 36, Issue 9, 1996, Pages 809-813

  Fleishaker, Joseph C ^a   Peters, Gary R ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

21 [4 [2,6 BIS(1 PYRROLIDINYL) 4 PYRIMIDINYL] 1 PIPERAZINYL] 16ALPHA METHYLPREGNA 1,9(11) DIENE 3,20 DIONE; ACETYLSALICYLIC ACID; ANALGESIC AGENT; ANTICOAGULANT AGENT; CARDIOVASCULAR AGENT; DRUG METABOLITE; HEPARIN; PLACEBO; TIRILAZAD; UNCLASSIFIED DRUG;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CEREBROVASCULAR ACCIDENT; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MAINTENANCE THERAPY; MALE; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0029761817     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1002/j.1552-4604.1996.tb04254.x     Document Type: Article

References (17)

1. Braughler JM, Hall ED, Jacobsen J, McCall JM, Means ED: The 21-aminosteroids: potent inhibitors of lipid peroxidation for the treatment of central nervous system trauma and ischemia. Drugs Future 1989;14:143-152.
2. Kassell NF, Haley EC, Apperson-Hansen C, Alves WM, and the participants: A randomized, double-blind, vehicle-controlled trial of tirilazad mesylate in patients with aneurysmal subarachnoid hemorrhage: a cooperative study in Europe/Australia/New Zealand. J Neurosurg 1996;84:221-228.
3. Kassell NF, Haley EC, Alves WM, Hansen CA, Weir B, and participants: Phase two trial of tirilazad in aneurysmal subarachnoid hemorrhage (abstract). Can J Neurol Sci 1993;20(Suppl 1):S29.
4. Bleck TP, Germanson TP, Jane JA, and the Participants in the Tirilazad Head Trauma Trial: Phase II. Tirilazad mesylate is safe in patients with moderate or severe head trauma (abstract). Neurology 1995;45(Suppl 4):A345.
5. Haley EC, for the STIPAS Investigators: Safety study of tirilazad mesylate in patients with acute ischemic stroke. Stroke 1994;25: 418-423.
6. Fleishaker JC, Peters GR, Cathcart KS: Evaluation of the pharmacokinetics and tolerability of tirilazad mesylate, a 21-aminosteroid free radical scavenger. I. Single-dose administration. J Clin Pharmacol 1993;33:175-181.
7. Hulst LK, Fleishaker JC, Peters GR: Single dose proportionality of tirilazad mesylate pharmacokinetics in healthy male volunteers [abstract]. Pharm Res 1993;10(Suppl):S-334.
8. Smith SL, Scherch HM, Hall ED: Protective effects of tirilazad mesylate and metabolite U-89678 against blood-brain barrier damage after subarachnoid hemorrhage and lipid peroxidative neuronal injury. J Neurosurg 1996;84:229-233.
9. Fleishaker JC, Hulst LK, Peters GR: Multiple dose tolerability and pharmacokinetics of tirilazad mesylate at doses of up to 10 mg/kg/day administered over 5-10 days in healthy volunteers. Int J Clin Pharmacol Ther 1994;32:223-230.
10. Wienkers LC, Steenwyk RC, Sanders PE, Pearson PG: Biotransformation of tirilazad in humans. I. Cytochrome P450 3A-mediated hydroxylation of tirilazad mesylate in human liver microsomes. J Pharmacol Exp Ther 1996;277:982-990.
11. Fleishaker JC, Hulst-Pearson LK, Peters GR: The effect of phenytoin on the pharmacokinetics of tirilazad mesylate in healthy male volunteers. Clin Pharmacol Ther 1994;56:389-397.
12. Fleishaker JC, Pearson LK, Peters GR: Gender does not affect the degree of induction of tirilazad clearance by phenobarbital. Eur J Clin Pharmacol 1996;50:139-145.
13. Fleishaker JC, Pearson PG, Wienkers LC, Pearson LK, Peters GR: Biotransformation of tirilazad in humans. II. Effect of ketoconazole on tirilazad clearance and oral bioavailability. J Pharmacol Exp Ther 1996;277:991-998.
14. Fleishaker JC, Hulst-Pearson LK, Peters GR: Effect of gender and menopausal status on the pharmacokinetics of tirilazad mesylate in healthy subjects. Am J Ther 1995;2:553-560.
15. Hulst LK, Fleishaker JC, Peters GR, Harry, JD, Wright DM, Ward P: Effect of age and gender on tirilazad pharmacokinetics in humans. Clin Pharmacol Ther 1994;55:378-384.
16. Orgogozo JM, Asplund K, Boysen G: A unified form for neurological scoring of hemispheric stroke with motor impairment. Stroke 1992;23:1678-1679.
17. SAS Institute: SAS User's Guide: Statistics. Version 5. Cary, NC: SAS Institute, Inc., 1985.